Amgen (AMGN) Reports Q4 Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. MSFT
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to Amgen (AMGN) Reports Q4 Beat

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

February 7, 2022 4:01 PM EST

THOUSAND OAKS, Calif., Feb. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results include:

For the fourth quarter, total revenues increased 3% to $6.8 billion in comparison to the fourth quarter of 2020, driven by increased Other Revenue from the Eli Lilly and Company (Lilly) COVID-19 manufacturing collaboration. Product sales decreased 1% globally for the fourth quarter. Volumes grew double-digits for a number of products including Prolia® (denosumab), MVASI® (bevacizumab-awwb), Repatha® (evolocumab) and EVENITY®... More